Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.55 |
| ▸ | GBA1 | P04062 | 8/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489327 | 1.00 | HRH4 (0.57) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL20375486 | 0.98 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL19300362 | 0.96 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL22762136 | 0.96 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18489275 | 0.96 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18494157 | 0.96 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18493347 | 0.96 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL19479091 | 0.96 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL3536093 | 0.94 | HRH4 (0.55) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL12265820 | 0.94 | HRH4 (0.55) | HRH4HRH3CYP19A1GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10253067-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10022422-B2 | Peptidomimetic macrocycles | Alleron Therapeutics, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9790262-B2 | Compositions comprising glucagon analogs and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782454-B2 | Highly active polypeptides and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-8399405-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193423-A1 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | APLNR, SCTR, GIPR | HRH4 1253/4885HRH3 1725/4885CYP19A1 3820/4885 |
| US-10253067-B2 | Peptidomimetic macrocycles and uses thereof | TP53, TP53BP1, MDM2 | HRH4 4696/4885HRH3 4678/4885CYP19A1 994/4885 |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | HRH4 1851/4885HRH3 2016/4885CYP19A1 1614/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | HRH4 4460/4885HRH3 3972/4885CYP19A1 2899/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | HRH4 1806/4885HRH3 1158/4885CYP19A1 2366/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | HRH4 4083/4885HRH3 3193/4885CYP19A1 1866/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | HRH4 4334/4885HRH3 3879/4885CYP19A1 3811/4885 |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | IL33, TPR, CDC37 | HRH4 1115/4885HRH3 912/4885CYP19A1 2898/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | HRH4 4460/4885HRH3 3972/4885CYP19A1 2899/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | HRH4 4246/4885HRH3 3700/4885CYP19A1 3250/4885 |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | HRH4 1253/4885HRH3 1725/4885CYP19A1 3820/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | HRH4 4334/4885HRH3 3879/4885CYP19A1 3811/4885 |
| US-10022422-B2 | Peptidomimetic macrocycles | HAVCR2, ZC3HAV1, ZC3HAV1L | HRH4 2819/4885HRH3 2156/4885CYP19A1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.